Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2018

  • ID: 4590315
  • Drug Pipelines
  • 101 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AC Immune SA
  • BioArctic AB
  • Denali Therapeutics Inc
  • Genmab A/S
  • MedImmune LLC
  • nLife Therapeutics SL
  • MORE
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2018

Summary:

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 38 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha Synuclein - Pipeline Review, H2 2018, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 19 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Alzheimer's Disease, Lewy body Dementia, Neurodegenerative Diseases, Amyloidosis, Constipation, Down Syndrome, Familial Amyloid Neuropathies, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Huntington Disease, Metastatic Breast Cancer, Schizophrenia, Spinal Cord Injury, Traumatic Brain Injury and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
  • The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AC Immune SA
  • BioArctic AB
  • Denali Therapeutics Inc
  • Genmab A/S
  • MedImmune LLC
  • nLife Therapeutics SL
  • MORE
Introduction

Report Coverage

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development

AC Immune SA

AFFiRiS AG

BioArctic AB

Biogen Inc

Denali Therapeutics Inc

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

MedImmune LLC

Neuropore Therapies Inc

nLife Therapeutics SL

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

QR Pharma Inc

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles

ABL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASD-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1947D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1948D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1949D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-0805 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-054 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-82422 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-1341 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLFPD-1233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-10018A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Posiphen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

quinpramine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trehalose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones

Featured News & Press Releases

Jun 26, 2018 : ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

Jun 19, 2018 : Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson's Disease Published In JAMA Neurology

Jun 18, 2018 : New immunotherapy could stop progression of Parkinson’s disease

May 14, 2018 : AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinson's Disease Patients

Mar 28, 2018 : Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM-Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis

Mar 26, 2018 : Enterin's Phase 2a RASMET Study in Patients With Parkinson's Disease Completes Enrollment

Mar 15, 2018 : AC Immune prepares for a first in human study of a promising positron emission tomography tracer for Parkinson's disease

Mar 01, 2018 : AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD01A

Mar 01, 2018 : AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD03A

Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy

Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT088 at Society for Neuroscience Annual Meeting

Nov 14, 2017: Proclara Biosciences Presents New Preclinical Data on GAIM-Based Therapy NPT189 at Society for Neuroscience Annual Meeting

Oct 13, 2017: BioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe

Jul 18, 2017: Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC)

Jul 17, 2017: Proclara Biosciences Announces Pipeline Progress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1)

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AC Immune SA, H2 2018

Pipeline by AFFiRiS AG, H2 2018

Pipeline by BioArctic AB, H2 2018

Pipeline by Biogen Inc, H2 2018

Pipeline by Denali Therapeutics Inc, H2 2018

Pipeline by Fulcrum Therapeutics Inc, H2 2018

Pipeline by Genmab A/S, H2 2018

Pipeline by ICB International Inc, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Neuropore Therapies Inc, H2 2018

Pipeline by nLife Therapeutics SL, H2 2018

Pipeline by Priavoid GmbH, H2 2018

Pipeline by ProMIS Neurosciences Inc, H2 2018

Pipeline by Prothena Corp Plc, H2 2018

Pipeline by QR Pharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AC Immune SA
  • AFFiRiS AG
  • BioArctic AB
  • Biogen Inc
  • Denali Therapeutics Inc
  • Fulcrum Therapeutics Inc
  • Genmab A/S
  • ICB International Inc
  • MedImmune LLC
  • Neuropore Therapies Inc
  • nLife Therapeutics SL
  • Priavoid GmbH
  • ProMIS Neurosciences Inc
  • Prothena Corp Plc
  • QR Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll